Benefits
Blood Sugar Regulation
A pooled analysis of 28 randomized trials, all in people with diagnosed type 2 diabetes, found chromium lowered fasting glucose by about 19 mg/dl and HbA1c by about 0.71 percentage points. Glucose results varied enormously between trials, and the true drop could plausibly be under 2 mg/dl. This says little about healthy adults, and chromium is not a diabetes treatment. If you take glucose-lowering medication, talk to your doctor first.
Metabolism Support
Chromium might play a role in carbohydrate, fat and protein metabolism by strengthening insulin action, although the mechanism has not been identified. The studies cited on this page measured blood sugar, blood lipids, blood pressure and memory, not energy use or metabolic rate.
Weight Management
Chromium is heavily marketed for weight loss and appetite control. Pooled analyses of trials in people with overweight or obesity found only about 0.5 to 1.1 kg more weight loss than placebo, of uncertain clinical relevance, and one review rated the evidence low quality. A trial in 52 people with type 2 diabetes saw no significant change in weight over 8 weeks, and effects on appetite are not established.
Cholesterol Levels
A small 8-week trial in 52 people with type 2 diabetes found modestly lower total and LDL cholesterol with 400 mcg a day of chromium picolinate than with placebo. A pooled analysis of 64 trials also reported better lipid values, but results varied with diabetes status and study location, and its authors called for bigger, longer trials. This does not replace cholesterol care from your doctor.
Mechanism of action
Insulin Sensitization
The proposed mechanism is that chromium supports insulin signaling and helps move the glucose transporter GLUT4 to the cell surface, which would improve glucose uptake. This comes from laboratory work, not from the human studies cited on this page.
Metabolic Regulation
Chromium is thought to form part of a molecule called chromodulin, which may amplify insulin’s effects on carbohydrate, fat, and protein metabolism.
Lipid Metabolism
One proposed mechanism is that chromium influences enzymes involved in cholesterol production. This is theory only; none of the human studies cited on this page tested it.
Clinical trials
Randomized controlled trial of chromium picolinate (400 µg/day) vs placebo in 52 T2DM patients over 8 weeks. Outcomes: fasting glucose, insulin resistance (HOMA-IR), lipid profile, weight and BMI. (Talab et al. 2020, Clin Nutr Res)
52 T2DM patients. 8-week intervention.
Compared with placebo at 8 weeks, the chromium group had lower insulin resistance (HOMA-IR) and modestly better total and LDL cholesterol after adjusting for baseline values. Fasting blood glucose, weight and BMI did not change significantly. It was a small, short trial in people with diagnosed type 2 diabetes who kept their usual medication, so it says nothing about healthy adults.
Randomized controlled trial of chromium-enriched yeast (400 µg/day chromium) vs placebo in 36 people with well-controlled T2DM over 12 weeks, double-blind. Outcomes: fasting glucose, HbA1c, fasting insulin, blood lipids, oxidative stress markers. (Racek et al. 2006, Biol Trace Elem Res)
36 adults with well-controlled T2DM (19 chromium, 17 placebo), mean age 61.3 years.
Compared with placebo, fasting serum glucose fell significantly in the chromium group. HbA1c stayed essentially unchanged on chromium while it drifted up slightly on placebo (6.94% to 7.11%), and fasting insulin fell in both groups (16.5% on chromium vs 9.5% on placebo). The trial was small, and it did not compare yeast with other chromium forms. Never adjust diabetes medication because of a supplement without your doctor.
Research letter pooling 64 randomized trials (34 in T2DM, 30 in people without T2DM) on glucose, HbA1c, fasting insulin, lipids and blood pressure, with a dose-response analysis. (Wan et al. 2023, JACC Adv)
Pooled across 64 randomized trials, 3,004 adults aged 18 to 90.
Overall, chromium was linked to lower glycemic markers, better blood lipids and lower systolic but not diastolic blood pressure. In T2DM, glycemic markers, HDL cholesterol and triglycerides improved, and 400 µg/day or more looked appropriate for fasting glucose. In people without T2DM, fasting glucose and lipids other than LDL improved. The authors noted heterogeneity and short trials and called for larger, longer, high-quality trials.
Evidence review and pooled analysis of 10 randomized trials (624 participants) assessing chromium supplementation effects on systolic and diastolic blood pressure. (Ghanbari et al. 2022, Eur J Clin Nutr)
Pooled across 10 randomized trials, 624 adults.
This is a null result: chromium did not significantly change systolic or diastolic blood pressure, and subgroups split by dose and by duration showed no significant change either. Another pooled analysis on this page reported lower systolic pressure overall, seen in Western but not non-Western trials, so the evidence is inconsistent. Chromium should not be taken for blood pressure.
Double-blind randomized controlled trial in 26 older adults with early memory decline receiving chromium picolinate vs placebo for 12 weeks. Memory testing, with fMRI imaging in a subset. (Krikorian et al. 2010, Nutr Neurosci)
26 older adults with early memory decline. 12-week intervention.
Learning rate and memory retention did not improve with chromium. The authors reported less semantic interference on some memory tasks and more brain activation on fMRI in a subset of participants. It was very small, 26 people, all older adults who already had cognitive decline, and no replication is cited here. It is not a reason to take chromium for memory.